The Compounding Pharmacy Wars

The fight between brand-name pharmaceutical companies and compounding pharmacies is not new and it is not about to end. It is a structural conflict between two pricing models, and it will keep happening as long as compounding pharmacies can legally produce the same molecules that brand-name drug companies sell for twenty or fifty or a hundred times more.

This article is a short history of that fight, a map of the tactics, and a guide to what patients should watch for next. For the baseline on how compounding actually works, see Compounding Pharmacies Explained. For the deeper reference, see the compounding wiki. For the specific case study of the recent peptide fight, see Peptide Access After the Kennedy HHS Announcement.

Why the fight exists

The cost structure of a compounded medication looks nothing like the cost structure of a brand-name pharmaceutical. The active pharmaceutical ingredient is cheap for most of the molecules under dispute. The labor to compound is modest. A PCAB-accredited 503A pharmacy can produce a month of testosterone cypionate for under $30, a month of compounded semaglutide for under $100, and a month of compounded sermorelin for under $60. The patient pays a modest markup, a provider adds a fee, and the total monthly cost is a fraction of the brand-name alternative.

The brand-name alternative exists because a pharmaceutical company spent years and billions running clinical trials, securing FDA approval, and building the supply chain to bring the drug to market. It priced the product to recover those costs plus a margin, and in the United States the resulting prices are higher than almost any other market on earth.

These two models can coexist when compounding is a niche. Custom doses for specific patients, formulations for allergies, molecules the pharma companies did not bother to commercialize. That is the traditional compounding scope and pharma has generally tolerated it. The fight starts when compounding scales into the mainstream of a drug category and begins to discipline the pricing of the brand-name version.

That is the story of the last fifteen years in compounding. Category by category, compounded alternatives have gotten better, more accessible, and more widely used. Testosterone. Thyroid. Sermorelin. Semaglutide. Peptides. Each time a category tips, the brand-name companies in that category push back. The tactics are consistent. The battleground rotates.

The 2012 NECC disaster

Any honest history of compounding has to start with the 2012 New England Compounding Center fungal meningitis outbreak. NECC, a compounding pharmacy in Massachusetts, shipped contaminated methylprednisolone acetate injections to medical facilities across the country. Sixty-four people died. More than seven hundred and fifty were sickened.

The NECC outbreak was a real failure. It was not a story of pharma smearing a competitor. It was a story of a compounding facility operating at industrial scale without the quality controls required for industrial-scale production. The facility was understerile, understaffed in quality assurance, and producing drugs in quantities that put it closer to a pharmaceutical manufacturer than a traditional compounding pharmacy.

The response was the 2013 Drug Quality and Security Act, which formalized the distinction between 503A pharmacies (patient-specific, regulated primarily by state pharmacy boards) and 503B outsourcing facilities (larger scale, regulated more like manufacturers with full FDA oversight). The law was a real improvement in how compounding is overseen. It is also the same law that gives the FDA the authority to place specific drugs on the Difficult to Compound list and otherwise constrain 503A practice.

The framing matters. Quality control in compounding is a legitimate concern. The 2013 law was a reasonable response to a real failure. Subsequent use of the same regulatory authority to restrict specific categories, some of which have real safety concerns and some of which do not, is where the fight gets complicated.

The thyroid battle

One of the early modern compounding fights was over desiccated thyroid and compounded liothyronine. Patients who did not respond well to synthetic T4 (levothyroxine, sold as Synthroid and others) often felt better on desiccated thyroid or on combination T4/T3 therapy. The compounded versions of those options were widely available and widely used by endocrinologists and functional medicine physicians.

Starting in the mid-2010s, a series of FDA actions and industry pressure campaigns targeted compounded thyroid therapy. The arguments were about standardization, consistency, and the availability of FDA-approved alternatives. The effect was to narrow the scope of compounded thyroid practice and to push patients back toward the brand-name synthetic options.

This was before the semaglutide era and the peptide era. It did not get the attention they did. But it established the pattern: a compounded category gains traction, the pharma companies in that category push back through regulatory and advocacy channels, and the scope of legal compounding narrows.

The semaglutide era

The GLP-1 story is the most visible compounding fight in recent memory. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) launched at prices in the $900-1,300 per month range for the brand-name versions. Insurance coverage was spotty. Patient demand was enormous. Compounded versions became available through 503A pharmacies at prices of $200-400 per month, opening access to a patient population that could not afford the brand-name products.

The legal basis for compounded semaglutide was section 503A(b) of the Federal Food, Drug, and Cosmetic Act, which permits compounding of drugs on the FDA’s shortage list. Semaglutide and tirzepatide were on the shortage list for much of 2022-2024 because Novo Nordisk and Eli Lilly could not produce them fast enough to meet demand.

Novo Nordisk and Lilly pushed back hard. They argued that compounded versions were unsafe, that the API sourcing was uncertain, and that the shortage basis was being abused. They filed lawsuits, funded safety advocacy, and lobbied the FDA to remove the drugs from the shortage list (which would end the legal basis for 503A compounding). By late 2024 and into 2025, the shortage status was removed for tirzepatide and then for semaglutide, and the legal path for 503A compounding narrowed significantly.

The fight is not over. The 503B outsourcing facility path is separate. Some compounders switched to formulating related molecules rather than the exact brand-name versions. Some patients moved to other compounded options. The legal and regulatory landscape continues to shift month to month.

What the semaglutide episode made clear is that the pharmaceutical industry will spend real resources to eliminate compounded alternatives the moment those alternatives become a meaningful threat to brand-name revenue. The arguments offered in public are about safety and standardization. The incentive structure underneath is about revenue protection.

The 2023-2026 peptide chapter

The peptide fight followed a similar arc with a different ending.

In late 2023, the FDA placed 14 commonly compounded peptides on the Difficult to Compound list, effectively cutting off legal 503A access. The cited reasons included safety, characterization, and the lack of pharmaceutical-grade reference standards for some peptides. Some of these concerns were legitimate. Peptide characterization is harder than small-molecule characterization. API sourcing in the peptide space is more variable. There were real quality issues at some compounders.

Other aspects of the decision were harder to defend. Several of the restricted peptides had been compounded legally for years with no documented safety signal. The removal of legal access did not make patients stop wanting the compounds. It pushed demand into the gray market, where quality was genuinely uncontrolled. The patient advocacy response was organized and substantive, and in February 2026 HHS reversed parts of the decision, restoring legal access to the 14 peptides.

The peptide chapter is the rare case where the patient access side won the fight. That is a useful data point but not a pattern. It happened because the advocacy was well-organized, the administration had changed, and the policy basis for the original decision was weaker than usual. None of those conditions will always hold.

What pharma actually does

Over all of these episodes, the tactics pharma uses against compounding are the same. Understanding the playbook helps patients read news coverage of the next fight with clearer eyes.

FDA petitions. Brand-name companies routinely file citizen petitions asking the FDA to restrict specific compounded products. The petitions cite safety concerns, characterization difficulties, and the availability of approved alternatives. Some petitions are granted, some are denied, most sit in limbo for years.

State pharmacy board lobbying. State boards regulate 503A practice directly. Pharma industry groups lobby states to add restrictions on specific products, specific compounding practices, or the sourcing of specific APIs. State-level friction varies widely as a result.

Litigation. Direct lawsuits against compounding pharmacies or against state agencies that have not acted on industry complaints. The semaglutide litigation is the most visible recent example.

Safety messaging. Funding and amplifying research that emphasizes safety risks of compounding, including studies in industry-friendly journals. Some of the research is legitimate. Some of it is framed to support a specific policy outcome.

Insurance pressure. Working with insurance companies and pharmacy benefit managers to refuse coverage for compounded versions of brand-name drugs, which narrows the pool of patients who can afford the compounded option without the brand-name pricing leverage.

Shortage list management. For drugs where the legal basis for compounding depends on a shortage status, pharma companies work to demonstrate that the shortage has resolved, which removes the compounding authority.

Professional society influence. Funding research, continuing medical education, and clinical guidelines through professional societies that then issue positions favorable to brand-name products.

None of these tactics are illegal. Most of them have legitimate uses in other contexts. They become part of a compounding fight when they are deployed in coordination against a specific category where compounded alternatives have become a threat to brand-name revenue.

What patients should watch for

For men using compounded testosterone, peptides, or GLP-1s, the compounding fight is the infrastructure your access depends on. A few things worth keeping an eye on:

FDA Drug Shortage List updates. Changes in shortage status for semaglutide, tirzepatide, or other GLP-1 drugs directly affect compounded GLP-1 access.

Difficult to Compound list changes. Additions to this list restrict 503A compounding of specific products. The list is updated periodically and the peptide reversal in 2026 showed that it can move in both directions.

State pharmacy board actions. State-level restrictions are often the first sign of where national pressure is building. Patients in restrictive states sometimes lose access before patients in permissive states.

Lawsuits against specific compounders. Named litigation often signals that a larger fight is in progress. The compounders who get sued first are often the ones at the edge of the regulatory gray area, but the outcomes set precedents that affect the rest of the category.

Insurance coverage changes. When a major insurer stops covering a compounded product, it is usually downstream of regulatory pressure and sometimes upstream of a broader restriction.

The honest framing is that the compounding model is a load-bearing piece of affordable men’s health care, the fight over it is a permanent feature of the landscape, and patients who depend on it should know enough about how the fight works to not be surprised by the next round. Compounding is a cost discipline on the pharmaceutical industry, and the industry has every incentive to push back against that discipline. The question is not whether the next fight will happen. The question is which category it will be in and how the patient access side will hold up.